Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Belantamab Mafodotin vs. Daratumumab for Multiple Myeloma
Recruiting2 awardsPhase 3
Detroit, Michigan
This trial is comparing two different treatments for relapsed myeloma. One is the standard of care, daratumumab + bortezomib/dexamethasone, and the other is a new drug, belantamab mafodotin, + bortezomib/dexamethasone. The trial will evaluate how well each works and if one is better than the other.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.